Veltin is a drug owned by Almirall Llc. It is protected by 2 US drug patents filed from 2013 to 2016. Out of these, 1 drug patents are active and 1 has expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 31, 2025. Details of Veltin's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9492384 | Microemulsion and sub-micron emulsion process and compositions |
Aug, 2025
(9 months from now) | Active |
| US5690923 | Stable topical retinoid compositions |
Nov, 2014
(9 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Veltin's patents.
Latest Legal Activities on Veltin's Patents
Given below is the list of recent legal activities going on the following patents of Veltin.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 18 Apr, 2024 | US9492384 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Apr, 2020 | US9492384 |
| Patent Issue Date Used in PTA Calculation Critical | 15 Nov, 2016 | US9492384 |
| Recordation of Patent Grant Mailed Critical | 15 Nov, 2016 | US9492384 |
| Email Notification Critical | 27 Oct, 2016 | US9492384 |
| Issue Notification Mailed Critical | 26 Oct, 2016 | US9492384 |
| Dispatch to FDC | 17 Oct, 2016 | US9492384 |
| Application Is Considered Ready for Issue Critical | 14 Oct, 2016 | US9492384 |
| Issue Fee Payment Received Critical | 13 Oct, 2016 | US9492384 |
| Issue Fee Payment Verified Critical | 13 Oct, 2016 | US9492384 |
Several oppositions have been filed on Veltin's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Veltin's generic, the next section provides detailed information on ongoing and past EP oppositions related to Veltin patents.
Veltin's Oppositions Filed in EPO
Veltin has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 14, 2014, by Generics [Uk] Limited. This opposition was filed on patent number EP05775966A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP05775966A | May, 2014 | Henkel AG & Co. KGaA | Patent maintained as amended |
| EP05775966A | May, 2014 | Generics [UK] Limited | Patent maintained as amended |
US patents provide insights into the exclusivity only within the United States, but Veltin is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Veltin's family patents as well as insights into ongoing legal events on those patents.
Veltin's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Veltin's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 31, 2025 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Veltin Generic API suppliers:
Clindamycin Phosphate; Tretinoin is the generic name for the brand Veltin. 3 different companies have already filed for the generic of Veltin, with Actavis Mid Atlantic having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Veltin's generic
Alternative Brands for Veltin
Veltin which is used for managing symptoms and inflammation associated with atopic dermatitis., has several other brand drugs in the same treatment category and using the same active ingredient (Clindamycin Phosphate; Tretinoin). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Almirall |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Clindamycin Phosphate; Tretinoin. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |
|---|---|---|
| Bausch |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Clindamycin Phosphate; Tretinoin, Veltin's active ingredient. Check the complete list of approved generic manufacturers for Veltin
About Veltin
Veltin is a drug owned by Almirall Llc. It is used for managing symptoms and inflammation associated with atopic dermatitis. Veltin uses Clindamycin Phosphate; Tretinoin as an active ingredient. Veltin was launched by Almirall in 2010.
Approval Date:
Veltin was approved by FDA for market use on 16 July, 2010.
Active Ingredient:
Veltin uses Clindamycin Phosphate; Tretinoin as the active ingredient. Check out other Drugs and Companies using Clindamycin Phosphate; Tretinoin ingredient
Treatment:
Veltin is used for managing symptoms and inflammation associated with atopic dermatitis.
Dosage:
Veltin is available in gel form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1.2%;0.025% | GEL | Prescription | TOPICAL |